Camerini Roberto 4
4 · SCICLONE PHARMACEUTICALS INC · Filed Jun 16, 2011
Insider Transaction Report
Form 4
Camerini Roberto
Director
Transactions
- Exercise/Conversion
Non-Qualified Stock Option (right to buy)
2011-06-14−14,710→ 35,290 totalExercise: $1.24Exp: 2019-03-30→ Common Stock (14,710 underlying) - Exercise/Conversion
Non-Qualified Stock Option (right to buy)
2011-06-14−18,624→ 16,666 totalExercise: $1.24Exp: 2019-03-30→ Common Stock (18,624 underlying) - Exercise/Conversion
Non-Qualified Stock Option (right to buy)
2011-06-14−5,000→ 0 totalExercise: $2.23Exp: 2019-06-09→ Common Stock (5,000 underlying) - Exercise/Conversion
Common Stock
2011-06-14$3.01/sh+30,000$90,300→ 30,000 total - Exercise/Conversion
Common Stock
2011-06-14$2.23/sh+5,000$11,150→ 5,000 total - Exercise/Conversion
Non-Qualified Stock Option (right to buy)
2011-06-14−30,000→ 0 totalExercise: $3.01Exp: 2020-06-10→ Common Stock (30,000 underlying) - Exercise/Conversion
Common Stock
2011-06-14$1.24/sh+14,710$18,240→ 14,710 total - Sale
Common Stock
2011-06-14$5.01/sh−14,710$73,709→ 0 total - Sale
Common Stock
2011-06-14$4.96/sh−30,000$148,719→ 0 total - Exercise/Conversion
Common Stock
2011-06-14$1.24/sh+18,624$23,094→ 18,624 total - Sale
Common Stock
2011-06-14$4.96/sh−18,624$92,325→ 0 total - Sale
Common Stock
2011-06-14$4.96/sh−5,000$24,787→ 0 total
Footnotes (5)
- [F1]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.00 to $5.05.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.90 to $5.00.
- [F3]Granted under the Issuer's 2004 Outside Directors Stock Option Plan.
- [F4]Shares shall become exercisable in three equal annual installments beginning on the first anniversary of the date of grant, subject to the Outside Director's continuous service on Issuer's Board of Directors.
- [F5]Each option shall vest and become exercisable at the rate of one-twelfth of the shares subject to the option at the end of each one-month period from the date of grant except that, in the event of a change in control, any unexercisable or unvested portions of outstanding options shall be immediately exercisable and vested in full as of the date ten (10) days prior to the change in control, regardless of whether the option is assumed or substituted for by the acquirer.